iShares Core High Dividend ETF vs Organon & Co. Common Stock — how do they compare? iShares Core High Dividend ETF trades at $29.57 (market cap $15.11B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Core High Dividend ETF is far larger — about 4.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Organon & Co. Common Stock for 0 Days on average.
| HDV | OGN | |
|---|---|---|
Market Cap | $15.11B | $3.62B |
Volume | 2,559,662 | 2,892,999 |
52-Week High | $29.93 | $13.81 |
52-Week Low | $23.64 | $5.70 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →